CannaKids & CURE Pharmaceutical Announce Research Collaboration with Technion Institute in IsraelMay 31, 2017 -
CURE Pharmaceutical (CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that the CURE and the CannaKids partnership has entered into a strategic research collaboration with Technion Research and Development Foundation Ltd., wholly owned subsidiary of the Technion-Israel Institute of Technology, in order to research how different cannabinoid compounds within cannabis strains can be used to treat various subtypes of cancer.
Researchers from CURE’s Pharmaceutical Cannabinoid Division and Technion’s Laboratory of Cancer Biology and Cannabinoid Research will work together to research and identify how varying cannabinoid compounds within cannabis strains can affect various cancer subtypes. The results of the research will be used to predict how to match a cancer subtype with an effective cannabis extract in order to optimize treatment efficacy.
“When I first traveled to Israel to meet Professor Meiri and his team at Technion in search for more help for my own daughter’s brain tumor, I was elated to find groundbreaking research already taking place in a federally legal environment,” stated Tracy Ryan, CEO of CannaKids. “It is with great pride that we announce this alignment between CannaKids, CURE and Technion as we work towards ushering in a new line of cannabinoid therapies to the pharmaceutical marketplace for those suffering from both adult and pediatric cancers. We are in a brave new world of plant-based cannabinoid medicines, and it is an honor to be working alongside such brilliant minds.”
“This research partnership with Technion, which has one of the leading cannabis laboratories in the world, is a crucial step in our goal to bring new cancer-fighting cannabinoid molecules to market,” said Rob Davidson, CEO of CURE. “In this work the Technion team aims to clarify the antitumor effects of phytocannabinoids and terpenes on various cancer-driving mutations and pathways, as well as further elucidating the mechanism of the cannabinoid-mediated antitumor effects. This will allow not only the identification of new drug candidates but also will create the ability to optimize cannabis treatment options for patients. Together these options further efforts toward the creation of personalized medicine.”
Technion’s lab group recently discovered two new pathways that have been activated by cannabis extracts in cancer cells.
Technion is looking forward to this partnership and working with CURE to continue uncovering the vast therapeutic potential of the cannabinoids found in various cannabis species. Accumulating evidence indicates that cannabinoids have antitumor effects, as several studies have demonstrated the use of cannabinoids in being able to regress different cancer types. This research collaboration with CURE will help the company with their goal of determining which cannabis strains might be used to tackle different cancer cells and what cannabinoid compounds within the plant are responsible for the ability to kill these cells.
Earlier this month, CURE announced its formal entrance into the pharmaceutical cannabis sector, which in the U.S. is estimated to reach over $23 billion by 2020, according to ArcView Market Research. CURE’s goal is to bring new cannabinoid molecules to the market through the FDA regulatory process, while utilizing the company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options.
CannaKids is a California Cooperative that specializes in the creation of lab tested, and PhD scientist extracted cannabis oils. CannaKids supplies mold, pesticide and solvent free Honey Gold cannabis oil to children and adults who are suffering from cancer, autism, epilepsy, PTSD, Crohn’s disease, severe pain disorders, and so much more.
CannaKids is on a trajectory to being one of the world’s leaders for cannabinoid therapy based on scientific research, and is in collaboration with some of the top researchers, doctors, and hospitals in the world. CEO Tracy Ryan and her team at CannaKids are currently collaborating with the Technion Institute in Israel where they are legally studying the effects of cannabinoids on many cancer types. CannaKids is sharing all of their patient data that they have been meticulously collecting with Technion.
About CURE Pharmaceutical
Headquartered in Oxnard, California, CURE Pharmaceutical (CURE) is a fully integrated specialty pharmaceutical/bioscience company that leverages disruptive proprietary drug delivery technologies for a broad range of molecules serving the biopharmaceutical, veterinarian, medical foods and pharmaceutical cannabis markets. CURE develops its patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today, from its industry leading full service cGMP manufacturing facility. The Company’s mission is to deliver proven drugs in a fast and efficient manner and to improve quality of life.